Use, tolerability and compliance of spironolactone in the treatment of heart failure

BMC Clinical Pharmacology

Volumn 11, Issue , 2011, Pages

  Lachaine, Jean ^a   Beauchemin, Catherine ^a   Ramos, Elodie ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE; ALDOSTERONE ANTAGONIST;

ADULT; AGED; ARTICLE; BREAST DISEASE; DRUG TOLERABILITY; DRUG USE; FEMALE; GYNECOMASTIA; HEART FAILURE; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; FEMALE; HEART FAILURE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SPIRONOLACTONE;

EID: 79956213148     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-11-4     Document Type: Article

References (20)

1. McKelvie R. Heart Failure. Clinical Evidence. Electronic source 2009, Access date: 2011-04-21., http://www.clinicalevidence.bmj.com
2. Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, Heckman GA, Howlett JG, Ignaszewski A, Johnstone DE, Jong P, McKelvie RS, Moe GW, Parker JD, Rao V, Ross HJ, Sequeira EJ, Svendsen AM, Teo K, Tsuyuki RT, White M. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006, 22(1):23-45. 10.1016/S0828-282X(06)70237-9, 2538984, 16450016.
3. Ross H, Howlett J, Arnold JM, Liu P, O'Neill BJ, Brophy JM, Simpson CS, Sholdice MM, Knudtson M, Ross DB, Rottger J, Glasgow K. Treating the right patient at the right time: access to heart failure care. Can J Cardiol 2006, 22(9):749-754. 10.1016/S0828-282X(06)70290-2, 2560514, 16835668.
4. Martineau P, Frenette M, Blais L, Sauve C. Multidisciplinary outpatient congestive heart failure clinic: impact on hospital admissions and emergency room visits. Can J Cardiol 2004, 20(12):1205-1211.
5. Public Health Agency of Canada Tracking Heart Disease and Stroke in Canada. 2009, Ottawa, Public Health Agency of Canada.
6. Kaul P, McAlister FA, Ezekowitz JA, Bakal JA, Curtis LH, Quan H, Knudtson ML, Armstrong PW. Resource use in the last 6 months of life among patients with heart failure in Canada. Arch Intern Med 2011, 171(3):211-217. 10.1001/archinternmed.2010.365, 20937918.
7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341(10):709-717. 10.1056/NEJM199909023411001, 10471456.
8. Struthers AD. Impact of aldosterone on vascular pathophysiology. Congest Heart Fail 2002, 8(1):18-22. 10.1111/j.1527-5299.2002.00722.x, 11821624.
9. Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med 1999, 341(10):753-755. 10.1056/NEJM199909023411009, 10471464.
10. Bouvy ML, Heerdink ER, Herings RM. Long-term therapy with spironolactone. Pharm World Sci 2001, 23(4):132-134. 10.1023/A:1011859702495, 11599198.
11. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003, 327(7407):147-149. 10.1136/bmj.327.7407.147, 1126510, 12869459.
12. Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol 2010, 25(2):325-333. 10.1111/j.1440-1746.2009.06140.x, 20074146.
13. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology 2007, 133(5):1670-1689. 10.1053/j.gastro.2007.09.001, 17983810.
14. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992, 45(2):197-203. 10.1016/0895-4356(92)90016-G, 1573438.
15. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996, 78(8):902-907.
16. Hay E, Derazon H, Bukish N, Katz L, Kruglyakov I, Armoni M. Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. J Emerg Med 2002, 22(4):349-352. 10.1016/S0736-4679(02)00434-1, 12113843.
17. Webster J. Interactions of NSAIDs with diuretics and beta-blockers mechanisms and clinical implications. Drugs 1985, 30(1):32-41. 10.2165/00003495-198530010-00004, 2863124.
18. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, Hawkes AL. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Med J Aust 2006, 185(10):549-557.
19. Poole-Wilson PA. The Cardiac Insufficiency Bisoprolol Study II. Lancet 1999, 353(9161):1360-1361.
20. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325(5):293-302.